XIENCE Sierra vs. Orsiro

Strut thickness, as with many design considerations of drug-eluting stents (DES), is a balancing act: too thick and critical post-deployment aspects like endothealial coverage or blood flow could be at risk; too thin and mechanical metrics could be affected, such as weaker radial strength, compromised visbility, greater risk of dislodgement, and longitudinal stent deformation6-9. XIENCE balances this important design goal, as shown in acute thrombogenicity performance and clinical safety endpoints1.

Best Stent Retention on the Market2

XIENCE Sierra delivers market-leading stent retention, which is critical in challenging anatomy. Stent retention data6 show that XIENCE Sierra is:


Stronger Than Synergy


Stronger Than Orsiro


Stronger Than Resolute Onyx

Significantly Greater Radial Strength3

The stent design goal of a DES is to balance acute performance with mechanical strength while achieving exceptional pushability, crossability, and flexibility.

Radial Strength Average (mmHg) for 3.0 mm Size
XIENCE Sierra™




Significantly Lower
Radial Strength








Excellent Radiopacity4

Mechanical strength isn´t the only consideration when treating complex patients. Radiopacity is an important attribute of any DES, and XIENCE Sierra offers better visability compared to Orsiro.

Images taken at magnification 2 with 8 mass in front of beam. Tests performed by and data on file at Abbott.

5-years Randomized Data Shows Significantly Higher All-cause Mortality with Orsiro vs. XIENCE, and Numerically Higher TLF5

Biosicence Trial 5-Year Results

All-Cause Mortality at 5 Years
BIOSCIENCE Trial, n=1537





Target Lesion Failure

AP2947116-WBU Rev A

  1. XIENCE showed significant benefit compared to several DES and composite BMS in multiple large scale meta-analyses and other RCTs. Source: Palmerini, et al. The Lancet. 379:9824, 14-20 April 2012, pp. 1393-1402; Bangalore S, et al. Circ Cardiovasc Interv, Aug 6, 2013. doi: 10.1161/circinterventions.113.000415; Valgimigli, Effects of Cobal-chromium Everolimus eluting or bare metal stent on fatal and non-fatal cardiovascular events. A patient-level meta analysis. EuroPCR 2014; Serruys, PW, et al. RESOLUTE All Comers Trial, NEJM 2010. Published online June 16, 2010; Fajadet, J., et al. PLATINUM PLUS 30-day Poster, TCT 2012.
  2. Test performed and data on file at Abbott. 3.0 x 18 mm XIENCE Sierra(TM), Orsiro(TM), and Resolute Onyx(TM) texted. 3.0 x 20 mm Synergy(TM) tested. 
  3. Tests performed and data on file at Abbott. Radial data refers to 3.0 mm diameter and 18-20 mm lengths.
  4. Images taken at magnification 2 with 8" mass in front of beam. Tests performed and data on file at Abbott.
  5. Pilgrim T, et al. “Randomized comparison of an ultrathin strut cobalt-chromium biodegradable polymer sirolimus-eluting stent with a thin strut durable polymer everolimus-eluting stent for PCI – Final 5-year outcomes of the BIOSCIENCE trial” ESC 2018.
  6. Kolandaivelu et al.; Circulation 2011; 123; 1400-1409.
  7. Colombo et al.; J Amer Coll Cardiol 2002;40(6): 1021-1033.
  8. ISAR STEREO I, Kastrati et al.; Circulation 2001; 103; 2816-2821.
  9. ISAR STEREO II JACC Vol. 41, No. 8, 2003 April 16, 2003:1283-8.

You are about to leave the Abbott family of websites for a third party website.

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.

The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit the website?
Important safety information